Context Therapeutics (CNTX) Proxy filing summary

Executive summary

• The 2026 Annual Meeting will be held virtually on June 24, 2026, allowing shareholders to participate online, submit questions, and vote electronically.

• Proxy materials are distributed electronically to reduce costs and environmental impact, with paper copies available upon request.

• Shareholders of record as of April 27, 2026, are eligible to vote on four key proposals.

Voting matters and shareholder proposals

• Shareholders will vote on electing seven directors for one-year terms, ratifying CohnReznick LLP as auditor, amending the certificate of incorporation to increase authorized common stock from 200M to 300M shares, and potentially adjourning the meeting to solicit more proxies if needed.

• The board recommends voting in favor of all proposals.

• Shareholder proposals for the 2027 meeting must be submitted by December 29, 2026, with specific advance notice requirements.

Board of directors and corporate governance

• The board consists of seven members, all nominated for re-election, with a majority deemed independent under Nasdaq rules.

• Recent legal action led to changes: directors now serve one-year terms and may be removed with or without cause by majority shareholder vote.

• The board has Audit, Compensation, and Nominating and Corporate Governance Committees, each composed of independent directors.

• Corporate Governance Guidelines, Code of Conduct, and insider trading policies are in place and available online.